Single-chain recombinant clotting factor VIII (lonoctocog alfa): clinical experience in Russia
Despite significant progress in haemophilia treatment, achieved in Russia recently, number of unmet medical needs still exist in routine clinical practice. Particularly, the annual bleeding rates are still high, leading to frequent development of synovitis and haemophilic arthropathy, resulting in c...
Saved in:
| Main Author: | M. V. Kosinova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Open Systems Publication
2022-02-01
|
| Series: | Лечащий Врач |
| Subjects: | |
| Online Access: | https://journal.lvrach.ru/jour/article/view/886 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life
by: Ilaria Nichele, et al.
Published: (2024-04-01) -
ERRATUM: Recommendations of Expert Group of Polish Society of Pediatric Oncology and Hematology on use of immune tolerance induction (ITI) in pediatric patients with hemophilia A complicated by a factor VIII inhibitor
by: Magdalena Wojdalska, et al.
Published: (2025-01-01) -
Flap cover in a patient with severe haemophilia type A
by: Narender Manickavachakan, et al.
Published: (2017-05-01) -
The association of factor VIII activity levels with bleeding and quality of life in haemophilia a: findings from the European CHESS II study
by: Cheryl Jones, et al.
Published: (2025-06-01) -
Factor VIII delivery devices in haemophilia A. Barriers and drivers for treatment adherence
by: Isabel Fernández-Arias, et al.
Published: (2016-12-01)